Clinical status and optimal use of topotecan

ONCOLOGY

Volumn 11, Issue 11, 1997, Pages 1635-1646

  Takimoto, Chris H ^a   Arbuck, Susan G ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG MECHANISM; DRUG METABOLISM; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MAJOR CLINICAL STUDY; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; RADIOSENSITIZATION; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DNA TOPOISOMERASES, TYPE I; DRUG EVALUATION; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; NEOPLASMS; SAFETY; TOPOTECAN; TREATMENT OUTCOME;

EID: 0030665426     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. Burris HA, Fields SM: Topoisomerase I inhibitors: An overview of the camptothecin analogs. Hematol Oncol Clin North Am 8:333-355, 1994.
2. Creemers GJ, Lund B, Verweij J: Topoisomerase I inhibitors: Topotecan and irinotecan. Cancer Treat Rev 20:73-96, 1994.
3. Potmesil M: Camptothecins: From bench research to hospital wards. Cancer Res 54:1431-1439, 1994.
4. Takimoto CH, Arbuck SG: The Camptothecins. in: Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice, pp 463-484. Philadelphia, Lippincott-Raven, 1996.
5. Jaxel C, Kohn KW, Wani MC, et al: Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase 1 : Evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49:1465-1469, 1989.
6. Hertzberg KP, Caranfa MJ, Holden KG, et al: Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32:715-720, 1989.
7. Tamzawa A, Kohn KW, Pommier Y: Induction of cleavage in topoisomerase I c-DNA by topoisomerase I enzymes from calf thymus and wheat gen-n in the presence and absence of camptothecin. Nucleic Acids Res 21:5157-5166, 1993.
8. Fassberg J, Stella VJ: A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 81:676-684, 1992.
9. Nitiss JL: Roles of DNA topoisomerases in chromosomal replication and segregation. Adv Pharmacol 29:103-134, 1994.
10. Ikeda H: DNA topoisomerase-mediated illegitimate recombination. Adv Pharmacol 29:147-165, 1994.
11. Drolet M, Wu HY, Liu LF: Roles of DNA topoisomerases in transcription. Adv Pharmacol 29:135-146, 1994.
12. Jaxel C, Capranico G, Kerrigan D, et al: Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J Biol Chem 266:20418-20423, 1991.
13. Leteurtre F, Fesen M, Koblhagen G, et al: Specific interaction of camptothecin, a topoi- somerase I inhibitor, with guanine residues of DNA detected by photoactivation at 365 nm. Biochemistry 32:8955-8962, 1993.
14. Hslang YH, Lihou MG, Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077-5082, 1989.
15. Holm C, Covey JM, Kerrigan D, et al: Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res 49:6365-6368, 1989.
16. Del Bino G, Bruno S, Yi PN, et al: Apoptotic cell death triggered by camptothecin or temposide: The cell cycle specificity and effects of ionizing radiation. Cell Prolif 25:531-548, 1992.
17. Bertrand R, Solary E, Jenkins J, et al: Apoptosis and its modulation in human promyelocytic HL-60 cells treated with DNA topoisomerase I and II inhibitors. Exp Cell Res 207:388-397, 1993.
18. D'Arpa P, Beardmore C, Liu LF: Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 50:6919-6924, 1990.
19. Hochster H. Liebes L, Speyer J, et al: Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen. J Clin Oncol 12:553-559, 1994.
20. Creemers GJ, Gerrits CJ, Schellens JH, et al: Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. J Clin Oncol 14:2540-2545, 1996.
21. Hochster H, Speyer J, Wadler S, et al: Phase II study of topotecan (TPT) 21-day infusion in platinum-treated ovarian cancer: A highly active regimen. Proc Am Soc Clin Oncol 15:285, 1996.
22. Bjornsti MA, Benedetti P, Viglianti GA, et al: Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: Restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res 49:6318-6323, 1989.
23. Rowinsky EK, Adjel A, Donehower RC, et al: Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 12:2193-2203, 1994.
24. Glovanella BC, Stehlin JS, Wall ME, et al: DNA topoisomerase 1-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046-1048, 1989.
25. Masin JS, Berger SJ, Setrakian S, et al: Topoisomerase I activity in squamous cell carcinoma of the head and neck. Laryngoscope 105:1191-1196, 1995.
26. Husain I, Mohler JL, Seigler HF, et al: Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 54:539-546, 1994.
27. Madden KR, Champoux JJ: Overexpression of human topoisomerase I in baby hamster kidney cells: Hypersensitivity of clonal isolates to camptothecin. Cancer Res 52:525-532, 1992.
28. Perego P, Capranico G, Supino R, et al: Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types. Anticancer Drugs 5:645-649, 1994.
29. Goldwasser F, Bae I, Valenti M, et al: Topolsomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 55:2116-2121, 1995.
30. Dubrez L, Goldwasser F, Genne P, et al: The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia 9:1013-1024, 1995.
31. Nitiss J, Wang JC: DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci USA 85:7501-7505, 1988.
32. Beadler DR, Chang JY, Zhou BS, et al: Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines. Cancer Res 56:345-353, 1996.
33. Pommier Y, Leteurtre F, Fesen MR, et al: Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 12:530-542, 1994.
34. Tan KB, Mattem MR, Eng WK, et al: Nonproductive rearrangement of DNA topoisomerase I and II genes: Correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 81:1732-1735, 1989.
35. Woessner RD, Eng WK, Hofmann GA, et al: Camptothecin hyper-resistant P388 cells: Drug-dependent reduction in topoisomerase I content. Oncol Res 4:481-488, 1992.
36. Rubin E, Pantazis P, Bharti A, et al: Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitrocamptothecin. J Biol Chem 269:2433-2439, 1994.
37. Benedetti P, Fiorani P, Capuani L, et al: Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. Cancer Res 53:4343-4348, 1993.
38. Tamura H, Kohchi C, Yamada R, et al: Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res 19:69-75, 1991.
39. Kubota N, Kanzawa F, Nishio K, et al: Detection of topoisomerase 1 gene point mutation in CPT-11 resistant lung cancer cell line. Biochem Biophys Res Commun 188:571-577, 1992.
40. Kapoor R, Slade DL, Fujimori A, et al: Altered topoisomerase I expression in two sub-clones of human CEM leukemia selected for resistance to Camptothecin. Oncol Res 7:83-95, 1995.
41. Fujimori A, Harker WG, Kohlhagen G, et al: Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to Camptothecin. Cancer Res 55:1339-1346, 1995.
42. Saijo N, Nishio K, Kubota N, et al: 7-Ethyl-10-[4-(1 -piperidino)-1-piperidino] carbonyloxy Camptothecin: Mechanism of resistance and clinical trials. Cancer Chemother Pharmacol 34(suppl):S112-117, 1994.
43. Knab AM, Fertala J, Bjomsti MA: A camptothecin-resistant DNA topoisomerase I mutant exhibits altered sensitivities to other DNA topoisomerase poisons. J Biol Chem 270:6141-6148, 1995.
44. Yang CJ, Horton JK, Cowan KH, et al: Cross-resistance to Camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res 55:4004-4009, 1995.
45. Chang JY, Dethlefsen LA, Barley LR, et al: Characterization of camptothecin-resistant Chinese hamster lung cells, Biochem Pharmacol 43:2443-2452, 1992.
46. Chen AY, Yu C, Potmesil M, et al: Camptothecin overcomes MDR1-medialed resistance in human KB carcinoma cells. Cancer Res 51:6039-6044, 1991.
47. Hendricks CB, Rowinsky EK, Grochow LB, et al: Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 52:2268-2278, 1992.
48. Mattern MR, Hofmann GA, Polsky RM, et al: In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncol Res 5:467-474, 1993.
49. Hashimoto H, Chatterjee S, Berger NA: Mutagenic activity of topoisomerase I inhibitors. Clin Cancer Res 1:369-376, 1995.
50. Anderson RD, Borger NA: International Commission for Protection Against Environmental Mutagens and Carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents. Mutat Res 309:109-142, 1994.
51. Lamond JP, Wang M, Kinsella TJ, et al: Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation. Int J Radiat Oncol Biol Phys 36:361-368, 1996.
52. Berlin J, Schiller JH, Hutson PR, et al: Phase I clinical and pharmacokinetic study of dally topotecan with thoracic irradiation. Proc Am Assoc Cancer Res 37:164, 1996.
53. Rowinsky EK, Grochow LB, Hendricks CB, et al: Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 10:647-656, 1992.
54. Saltz L, Sirott M, Young C, et al: Phase I clinical and pharmacology study of topotecan given dally for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 85:1499-1507, 1993.
55. Verweij J, Lund B, Beijnen J, et al: Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 4:673-678, 1993.
56. Burris HA, Awada A, Kuhn JG, et al: Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 hour continuous infusion. Anticancer Drugs 5:394-402, 1994.
57. Kantarjian HM, Beran M, Ellis A, et al: Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 81:1146-1151, 1993.
58. Wall JG, Burris HA, Von Hoff DD, et al: A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs 3:337-345, 1992.
59. Haas NB, LaCreta FP, Walczak J, et al: Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res 54:1220-1226, 1994.
60. van Warmerdam LJ, ten Bokkel Humink WW, Rodenhuis S, et al: Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion. J Clin Oncol 13:1768-1776, 1995.
61. Blaney SM, Balis FM, Cole DE, et al: Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continu- ous infusion. Cancer Res 53:1032-1036, 1993.
62. Pratt CB, Stewart C, Santana VM, et al: Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 12:539-543, 1994.
63. Creemers GJ, Gerrits CJH, Eckardt JR, et al: Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol 15:1087-1093, 1997.
64. Plaxe S, Chritsen R, O'Quigley J: Phase I trial of intraperitoneal topotecan. Proc Am Soc Clin Oncol 12:140, 1993.
65. Grochow LB, Rowinsky EK, Johnson R, et al: Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos 20:706-713, 1992.
66. Rowinsky E, Sartorius S, Grochow L, et al: Phase I & pharmacologic study of topotecan, an inhibitor of topoisomerase I, with granulocyte colony-stimulating factor (G-CSF): Toxicologic differences between concurrent & post-treatment C-CSF administration. Proc Am Soc Clin Oncol 11: 116, 1992.
67. SmithKline Beecham: Package insert for topotecan HCl for injection (Hycamtin), 1996.
68. American Society of Clinical Oncology: Recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 12:2471-2508, 1994.
69. American Society of Clinical Oncology: Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines. J Clin Oncol 14:1957-1960, 1996.
70. Gerrits CJ, Eckardt JR, Schellens JHM, et al: Oral topotecan for 10 days b.i.d. every 3 weeks, results of a phase I and pharmacologic study in adults with solid tumors. Ann Oncol 7(suppl 1):132, 1996.
71. Lynch Jr. TJ, Kalish L, Strauss G, et al: Phase II study of topotecan in metastatic non-small-cel lung cancer. J Clin Oncol 12:347-352, 1994.
72. Stewart CF, Baker SD, Heideman RL, et al: Clinical pharmacodynamics of continuous infusion topotecan in children: Systemic exposure predicts hematologic toxicity. J Clin Oncol 12:1946-1954, 1994.
73. Creemers GJ, Schellens JHM, Beijnen JH, et al: Bioavailability of oral topotecan, a new topoisomerase I inhibitor. Proc Am Soc Clin Oncol 13:132, 1995.
74. Kuhn J, Rizzo J, Eckardt J, et al: Phase I bioavailability study of oral topotecan. Proc Am Soc Clin Oncol 14:474, 1995.
75. Burke TG, Mi Z: The structural basis of camptothecin interactions with human serum albumin: Impact on drug stability. J Med Chem 37:40-46, 1994.
76. Mi Z, Malak H, Burke TG: Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry 34:13722-13728, 1995.
77. Baker SD, Heideman RL, Crom WR, et al: Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Phannacol 37:195-202, 1996.
78. van Warmerdam LJ, Verweij J, Schellens JH, et al: Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother Pharmacol 35:237-245, 1995.
79. O'Reilly S, Rowinsky E, Slichenmyer W, et al: Phase I and pharmacologic studies of topotecan in patients with impaired renal function. J Clin Oncol 14:3062-3073, 1996.
80. O'Reilly S, Rowinsky E, Slichenmyer W, et al: Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. J Natl Cancer Inst 88:817-824, 1996.
81. Ten Bokkel Huinink W, Gore M, Carmichael J, et al: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193, 1997.
82. Gordon A, Bookman M, Malstrom H, et al: Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group trial. Proc Am Soc Clin Oncol 15:282, 1996.
83. Kudelka AP, Tresukosol D, Edwards CL, et al: Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14:1552-1557, 1996.
84. Creemers GJ, Bolis G, Gore M, et al: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol 14:3056-3061, 1996.
85. Schiller JH, Kim K, Hutson P, et al: Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: An Eastem Cooperative Oncology Group Trial. J Clin Oncol 14:2345-2352, 1996.
86. Perez-Soler R, Glission BS, Lee JS, et al: Phase II study of topotecan in patients with small cell lung cancer (SCLC) refractory to etoposide. Proc Am Soc Clin Oncol 14:355, 1995.
87. Wanders J, Ardizzoni A, Hansen HH, et al: Phase II study of topotecan in refractory and sensitive small cell lung cancer (SCLC). Proc Am Assoc Cancer Res 36:237, 1995.
88. Ardizzoni A, Hansen H, Dombemoswsky P, et al: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. J Clin Oncol 15:2090-2096, 1997.
89. Weitz JJ, Jung SH, Marschke FF, et al: Randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung carcinoma (NSCLC): A North Central Cancer Treatment Group (NCCTG) trial. Proc Am Soc Clin Oncol 14:348, 1995.
90. Perez-Soler R, Fossella FV, Glisson BS, et al: Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 14:503-513, 1996.
91. Beran M, Kantarjian H, O'Brien S, et al: Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myclomonocytic leukemia. Blood 88:2473-2479, 1996.
92. Greenberg PL: Myelodysplastic syndrome, in: Hoffman R, Benz EJ, Shattil SJ, et al (eds). Hematology: Basic Principles and Practice, pp 1109. New York, Churchill Livingstone, 1995.
93. Furman WL, Baker SD, Prall CB, et al: Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. J Clin Oncol 14:1504-1511, 1996.
94. O'Brien S, Kantarjian H, Ellis A, et al: Topotecan in chronic lymphocytic leukemia. Cancer 75:1104-1108, 1995.
95. Preti HA, Plunkett W, Sarris AH: Preliminary results of a phase II trial of topotecan in patients with relapsing lymphoma. Blood 86:820a, 1995.
96. Arbuck SG, Blaylock BA, Christian MC, et al: The camptothecin topoisomerase I inhibitors: An update, in: Hortobagyi GN, Khayat D (eds): Progress in Anti-Cancer Chemotherapy, pp 1-27. Oxford, Blackwell Science Ltd, 1997.
97. Seiter K, Feldman EJ, Halicka HD, et al: Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia. J Clin Oncol 15:44-51, 1997.
98. Kretschmar C, Kletzel M, Murray K, et al: Up front phase II therapy with TAXOL (Tx1) and topotecan in untreated children (> 365 days) with disseminated (INSS stage 4) neuroblastoma. Med Pediat Oncol 25:243, 1995.
99. Vietti T, Crist W, Ruby E, et al: Topotecan window in patients with rhabdomyosarcoma (RMS): An IRSG study. Proc Am Soc Clin Oncol 16:510a, 1997.
100. Creemers GJ, Wanders J, Gamucci T, et al: Topotecan in colorcctal cancer: A phase II study of the EORTC early clinical trials group. Ann Oncol 6:844-846, 1995.
101. Sugarman SM, Ajani JA, Daugherty K, et al. A Phase II trial of topotecan (TPT) for the treatment of advanced, measurable colorectal cancer. Proc Am Soc Clin Oncol 13:225, 1994.
102. Smith RE, Lew D, Rodriguez GI, et al: Evaluation of topolecan in recurrent or metastatic head and neck cancer. SWOG-9305. Proc Am Soc Clin Oncol 15.310, 1996
103. MacDonald D, Cairncross G, Stewart D, et al: Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group. Ann Oncol 7:205-207, 1996.
104. Burch PA, Novotony PJ, Bemath AM, et al: A North Central Cancer Treatment Group phase II trial of topotecan in relapsed gliomas. Proc Am Assoc Cancer Res 37:169-170, 1996.
105. Noda K, Sasaki H, Yamamoto K, et al: Phase II trial of topotecan for cervical cancer of the uterus. Proc Am Soc Clin Oncol 15:280, 1996.
106. Puc HS, Bajorin DF, Bosl GJ, et al: Phase II trial of topotecan in patients with cisplatinrefractory germ cell tumors. Invest New Drugs 13:163-165, 1995.
107. Maksymiuk AW, Jung S, Marschke RF, et al: Phase II trial of topotecan in pleural mesothelioma: North Central Cancer Treatment Group (NCCTG) trial Proc Am Soc Clin Oncol 14:435, 1995.
108. Kraut EH, Staubus A, Mayernick D, et al: Phase II trial of topotecan in metastatic malignant melanoma. Proc Am Assoc Cancer Res 36:238, 1995.
109. Hudes GR, Kosierowski R, Greenberg R, et al: Phase II study of topotecan in metastatic hormone-refractory prostate cancer. Invest New Drugs 13:235-240, 1995.
110. Giantomo BJ, Kosierowski R, Ramsey HE: Phase II study of topotecan (TT) for hormone-refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 12:A774, 1993.
111. Sugannan SM, Pazdur R, Daugherty K, et al: A Phase II trial of topotecan (TPT) for the treatment of unresectable pancreatic cancer. Proc Am Soc Clin Oncol 13:224, 1994.
112. Scher RM, Kosierowski R, Lusch C, et al: Phase II trial of topotecan in advanced or metastatic adenocarcinomaof the pancreas. Invest New Drugs 13:347-354, 1996.
113. Bramwell VH, Eisenhauer EA, Elacksteln M, et al: Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma. Ann Oncol 6:847-849, 1995.
114. Law TM, Ilson DU, Motzer RJ: Phase II triai of topotecan in patients with advanced renal cell carcinoma. Invest New Drugs 12:143-145, 1994.
115. Danks MK, Marion RC: Comparison of intermittent and continuous exposure to topotecan in medulloblastoma cells. Proc Am Assoc Cancer Res 37:436, 1996.
116. Miller AA, Hargis JB, Lilenbaum RC, et al: Phase I study of topotecan and cisplatin in patients with advanced solid tumors: A cancer and leukemia group B study. J Clin Oncol 12:2743-2750, 1994.
117. Rowinsky EK, Kaufmann SH, Baker SD. et al: Sequences of topotecan and cisplatin: Phase 1, pharmacologie, and in vitro studies to examine sequence dependence. J Clin Oncol 14:3074-3084, 1996.
118. Lilenbaum RC, Ratain MJ, Miller AA, et al: Phase I study of paclitaxel and topotecan in patients with advanced tumors: A cancer and leukemia group B study. J Clin Oncol 13:2230-2237, 1995.
119. Hochster H, Speyer J, Oratz R, et al: Phase I study of TAXOL with 14-day topotecan continuous low-dose infusions. Proc Am Soc Clin Oncol 14:486, 1995.
120. Murren JR, Fedele J, Andersen S, et al Phase I trial of cyclophosphamide and topotecan in refractory cancer. Proc Am Soc Clin Oncol 14:475, 1995.
121. Torcher AW, O'Shaughnessy JA, Weiss RB, et al: A phase I study of topotecan (a topoisomerase I inhibitor) in combination with doxorubicm (a topoisomerase II inhibitor). Proc Am Soc Clinc Oncol 13:157, 1994.
122. Eckardt JR, Burris HA, Von Hoff DD, et al: Measurement of tumor topoisomerase I and II levels during the sequential administration of topotecan and etoposide. Proc Am Soc Clin Oncol 13:141, 1994.
123. Herben VMM, ten Bokkel Huinink WW, Rodenhuls S, et al: Phase I and pharmacokinetic study of topotecan in combination with oral etoposide. Ann Oncol 1 (suppl 1).133, 1996.
124. Crump M, Lipton J, Medley D, et al: A phase I trial of sequential topotecan and etoposide in adult acute myeloid leukemia. Proc Am Soc Clin Oncol 15:357, 1996.
125. Cheng MF, Chatterjee S, Berger NA. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res 6:269-279, 1994.
126. Miller AA, Lilenbaum RC, Lynch TJ, et al: Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. J Clin Oncol 14:1964-1965, 1996.